Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AGY.L Stock Summary
Top 10 Correlated ETFs
AGY.L
In the News
AGY.L Financial details
Company Rating
Neutral
Market Cap
130.84M
Income
-56.85M
Revenue
132.36M
Book val./share
0
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
612
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-0.36
Forward P/E
-300
PEG
-0.01
P/S
2.11
P/B
-3.83
P/C
300
P/FCF
-3.73
Quick Ratio
0.78
Current Ratio
1.8
Debt / Equity
13.67
LT Debt / Equity
12.8
-
-
EPS (TTM)
-0.06
EPS next Y
-0.01
EPS next Q
-
EPS this Y
198.99%
EPS next Y
-83.71%
EPS next 5Y
-116.29%
EPS last 5Y
NAN%
Revenue last 5Y
-4.17%
Revenue Q/Q
-50.66%
EPS Q/Q
296.61%
-
-
-
-
SMA20
9.41%
SMA50
13850%
SMA100
96.48%
Inst Own
0%
Inst Trans
0%
ROA
-75%
ROE
79%
ROC
-0.68%
Gross Margin
57%
Oper. Margin
-55%
Profit Margin
-84%
Payout
-
Shs Outstand
4.77B
Shs Float
159.68M
-
-
-
-
Target Price
-
52W Range
0.8-6.25
52W High
-
52W Low
-
RSI
71.33
Rel Volume
0.18
Avg Volume
658.43K
Volume
120.4K
Perf Week
9.09%
Perf Month
25%
Perf Quarter
100%
Perf Half Y
150%
-
-
-
-
Beta
1.308
-
-
Volatility
0.12%, 0.15%
Prev Close
0%
Price
3
Change
7.14%
AGY.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.11 | 0.05 | 0.06 | 0.05 | 0.04 | |
Net income per share | 0.01 | 0 | 0 | -0.01 | -0.03 | |
Operating cash flow per share | 0.01 | 0.01 | 0.01 | -0.01 | -0.02 | |
Free cash flow per share | 0 | 0.01 | 0 | -0.01 | -0.02 | |
Cash per share | 0.04 | 0.03 | 0.03 | 0.01 | 0.01 | |
Book value per share | 0.06 | 0.03 | 0.03 | 0.03 | 0 | |
Tangible book value per share | 0.05 | 0.02 | 0.03 | 0.02 | 0 | |
Share holders equity per share | 0.06 | 0.03 | 0.03 | 0.03 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0.02 | |
Market cap | 42.2M | 94.22M | 169.19M | 133.4M | 7.04M | |
Enterprise value | 17.2M | 69.44M | 140.09M | 123.41M | 28.18M | |
P/E ratio | 12.17 | 13.35 | 58.63 | -9.68 | -0.16 | |
Price to sales ratio | 0.57 | 1.2 | 2.01 | 1.83 | 0.12 | |
POCF ratio | 7.54 | 7.68 | 19.87 | -9.45 | -0.23 | |
PFCF ratio | 15.13 | 9.68 | 28.42 | -7.77 | -0.2 | |
P/B Ratio | 1.12 | 2.15 | 3.49 | 3.53 | 3.41 | |
PTB ratio | 1.12 | 2.15 | 3.49 | 3.53 | 3.41 | |
EV to sales | 0.23 | 0.89 | 1.66 | 1.7 | 0.47 | |
Enterprise value over EBITDA | -17.2K | 8.3 | 20.68 | -13.97 | -0.92 | |
EV to operating cash flow | 3.07 | 5.66 | 16.45 | -8.75 | -0.91 | |
EV to free cash flow | 6.16 | 7.14 | 23.53 | -7.19 | -0.79 | |
Earnings yield | 0.08 | 0.07 | 0.02 | -0.1 | -6.12 | |
Free cash flow yield | 0.07 | 0.1 | 0.04 | -0.13 | -5.06 | |
Debt to equity | 0.06 | 0.12 | 0.09 | 0.1 | 13.67 | |
Debt to assets | 0.04 | 0.06 | 0.05 | 0.05 | 0.42 | |
Net debt to EBITDA | 25K | -2.96 | -4.3 | 1.13 | -0.69 | |
Current ratio | 2.77 | 3.03 | 3.17 | 2.35 | 1.81 | |
Interest coverage | -166.91 | 13.15 | 6.85 | -24.03 | -16.15 | |
Income quality | 1.62 | 1.74 | 2.95 | 1.02 | 0.72 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.24 | 0.25 | 0.25 | 0.29 | 0.42 | |
Research and developement to revenue | 0.09 | 0.12 | 0.15 | 0.22 | 0.34 | |
Intangibles to total assets | 0.07 | 0.1 | 0.09 | 0.11 | 0.12 | |
Capex to operating cash flow | -0.5 | -0.21 | -0.3 | 0.22 | 0.15 | |
Capex to revenue | -0.04 | -0.03 | -0.03 | -0.04 | -0.08 | |
Capex to depreciation | -1.53 | -0.65 | -0.62 | -0.73 | -1.11 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0 | |
Graham number | 0.08 | 0.06 | 0.04 | 0.08 | 0.03 | |
ROIC | -0.04 | 0.08 | 0.04 | -0.28 | -0.93 | |
Return on tangible assets | 0.05 | 0.09 | 0.04 | -0.21 | -0.73 | |
Graham Net | 0.01 | 0 | 0.01 | 0 | -0.03 | |
Working capital | 29.77M | 36.94M | 39.63M | 24.34M | 14.96M | |
Tangible asset value | 32.72M | 35.58M | 40.44M | 29.38M | -5.68M | |
Net current asset value | 15.69M | 12.73M | 18.3M | 7.21M | -31.18M | |
Invested capital | 0.06 | 0.12 | 0.09 | 0.1 | 13.67 | |
Average receivables | 4.16M | 6.28M | 7.15M | 8.35M | 8.78M | |
Average payables | 3.67M | 3.18M | 2.56M | 3.59M | 4.19M | |
Average inventory | 9.11M | 9.77M | 10.49M | 11.12M | 11.5M | |
Days sales outstanding | 22.24 | 37.69 | 26.93 | 52.51 | 43.42 | |
Days payables outstanding | 82.24 | 39.11 | 46.93 | 65.63 | 55.5 | |
Days of inventory on hand | 186.86 | 178.74 | 175.56 | 174.88 | 157.33 | |
Receivables turnover | 16.41 | 9.68 | 13.55 | 6.95 | 8.41 | |
Payables turnover | 4.44 | 9.33 | 7.78 | 5.56 | 6.58 | |
Inventory turnover | 1.95 | 2.04 | 2.08 | 2.09 | 2.32 | |
ROE | 0.09 | 0.16 | 0.06 | -0.36 | -20.85 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q4
Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.02 | 0.03 | 0.04 | 0.03 | 0.01 | |
Net income per share | -0.01 | 0 | -0.03 | -0.01 | -0.02 | |
Operating cash flow per share | 0 | 0 | -0.03 | -0.01 | -0.02 | |
Free cash flow per share | 0 | 0 | -0.03 | -0.01 | -0.02 | |
Cash per share | 0.03 | 0.03 | 0.03 | 0.01 | 0.01 | |
Book value per share | 0.03 | 0.04 | 0.06 | 0.03 | 0 | |
Tangible book value per share | 0.03 | 0.03 | 0.05 | 0.02 | 0 | |
Share holders equity per share | 0.03 | 0.04 | 0.06 | 0.03 | 0 | |
Interest debt per share | 0 | 0 | 0.01 | 0 | 0.02 | |
Market cap | 160.47M | 221.35M | 61.52M | 41.39M | 7.13M | |
Enterprise value | 131.37M | 189.89M | 51.53M | 35.97M | 28.27M | |
P/E ratio | -3.33 | 8.3 | -0.75 | -1.22 | -0.05 | |
Price to sales ratio | 5.3 | 4.55 | 2.56 | 1.04 | 0.36 | |
POCF ratio | -37.26 | 59.63 | -3.49 | -5.47 | -0.31 | |
PFCF ratio | -26 | 86.3 | -3.15 | -3.96 | -0.28 | |
P/B Ratio | 3.31 | 4.03 | 1.6 | 1.09 | 3.45 | |
PTB ratio | 3.31 | 4.03 | 1.6 | 1.09 | 3.45 | |
EV to sales | 4.34 | 3.9 | 2.14 | 0.9 | 1.44 | |
Enterprise value over EBITDA | -19.5 | 19.85 | -2.8 | -6.3 | -1.09 | |
EV to operating cash flow | -30.5 | 51.16 | -2.92 | -4.75 | -1.21 | |
EV to free cash flow | -21.29 | 74.03 | -2.64 | -3.44 | -1.13 | |
Earnings yield | -0.08 | 0.03 | -0.33 | -0.21 | -4.85 | |
Free cash flow yield | -0.04 | 0.01 | -0.32 | -0.25 | -3.52 | |
Debt to equity | 0.09 | 0.06 | 0.1 | 0.08 | 13.67 | |
Debt to assets | 0.05 | 0.04 | 0.05 | 0.04 | 0.42 | |
Net debt to EBITDA | 4.32 | -3.29 | 0.54 | 0.95 | -0.82 | |
Current ratio | 3.17 | 3.8 | 2.35 | 2.22 | 1.81 | |
Interest coverage | -35.48 | 35.13 | -43.34 | -19.64 | -13.68 | |
Income quality | 0.36 | 0.56 | 0.86 | 0.89 | 0.68 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.36 | 0.22 | 0.42 | 0.3 | 0.68 | |
Research and developement to revenue | 0.16 | 0.1 | 0.44 | 0.21 | 0.59 | |
Intangibles to total assets | 0.09 | 0.08 | 0.11 | 0.11 | 0.12 | |
Capex to operating cash flow | 0.43 | -0.31 | 0.11 | 0.38 | 0.08 | |
Capex to revenue | -0.06 | -0.02 | -0.08 | -0.07 | -0.09 | |
Capex to depreciation | -0.89 | -0.48 | -1.08 | -1.37 | -0.84 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.01 | 0 | 0 | |
Graham number | 0.08 | 0.06 | 0.21 | 0.06 | 0.03 | |
ROIC | -0.15 | 0.1 | -0.42 | -0.17 | -0.76 | |
Return on tangible assets | -0.15 | 0.08 | -0.31 | -0.13 | -0.59 | |
Graham Net | 0.01 | 0.01 | 0 | 0 | -0.03 | |
Working capital | 39.63M | 46.49M | 24.34M | 20.81M | 14.96M | |
Tangible asset value | 40.44M | 47.44M | 30.02M | 29.94M | -5.68M | |
Net current asset value | 18.3M | 26.09M | 7.21M | 4.21M | -31.18M | |
Invested capital | 0.09 | 0.06 | 0.1 | 0.08 | 13.67 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 18.48 | 19.91 | 39.14 | 26.38 | 32.4 | |
Days payables outstanding | 143.71 | 105.18 | 134.61 | 91.15 | 122.83 | |
Days of inventory on hand | 94.54 | 74.63 | 98.02 | 69.94 | 85.35 | |
Receivables turnover | 4.87 | 4.52 | 2.3 | 3.41 | 2.78 | |
Payables turnover | 0.63 | 0.86 | 0.67 | 0.99 | 0.73 | |
Inventory turnover | 0.95 | 1.21 | 0.92 | 1.29 | 1.05 | |
ROE | -0.25 | 0.12 | -0.53 | -0.22 | -16.73 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AGY.L Frequently Asked Questions
What is Allergy Therapeutics plc stock symbol ?
Allergy Therapeutics plc is a GB stock and trading under the symbol AGY.L
What is Allergy Therapeutics plc stock quote today ?
Allergy Therapeutics plc stock price is $3 today.
Is Allergy Therapeutics plc stock public?
Yes, Allergy Therapeutics plc is a publicly traded company.